Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
content:zonisamide [2020/02/13 15:52] – [Main ADRs] icna | content:zonisamide [2022/04/30 18:38] (current) – administrator@icnapedia.org | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Zonisamide ====== | ====== Zonisamide ====== | ||
- | + | Zonisamide is a synthetic 1,2-benzisoxazole derivative | |
- | Efficacy, dose and mean plasma levels were similar in multi-centre studies with Japanese and Caucasian subjects[(: | + | |
===== Authorised indications ===== | ===== Authorised indications ===== | ||
Line 11: | Line 9: | ||
* Zonisamide appears to be an effective broad-spectrum AED with extensive clinical use in Japan | * Zonisamide appears to be an effective broad-spectrum AED with extensive clinical use in Japan | ||
- | * It is efficacious in focal seizures with or without GTCSs, primarily and secondarily generalised seizures including epileptic spasms of [[West syndrome]], other epileptic encephalopathies such as [[content: | + | * It is efficacious in focal seizures with or without GTCSs, primarily and secondarily generalised seizures including epileptic spasms of [[West syndrome]], other epileptic encephalopathies such as [[content: |
==== Dosage and titration ==== | ==== Dosage and titration ==== | ||
Line 29: | Line 27: | ||
**Reference range:** 15–40 mg/l (45–180 μmol/l). | **Reference range:** 15–40 mg/l (45–180 μmol/l). | ||
+ | |||
+ | see [[https:// | ||
==== Main ADRs ==== | ==== Main ADRs ==== | ||
Line 43: | Line 43: | ||
* Additional severe ADRs are those seen with the sulfonamides, | * Additional severe ADRs are those seen with the sulfonamides, | ||
* Depression and psychosis may be common, particularly in children. In one study, 14 of 74 patients experienced psychotic episodes within a few years of commencement of zonisamide[(: | * Depression and psychosis may be common, particularly in children. In one study, 14 of 74 patients experienced psychotic episodes within a few years of commencement of zonisamide[(: | ||
- | * Seizure exacerbation: | + | * Seizure exacerbation: |
**Considerations in women** | **Considerations in women** | ||
Line 76: | Line 76: | ||
==== References ==== | ==== References ==== | ||
- | ~~refnotes cite~~ | + | ~~REFNOTES~~ |
- | Wroe SJ. Zonisamide. In: Shorvon S, Perucca E, Engel JJr, eds. The treatment of epilepsy (3nd edition). Oxford: Willey-Blackwell, | + | ~~AUTHORS~~ |
- | Willmore LJ, Seino M. International experiences and perspectives: | + | {{tag> |
- | Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002; | + | ~~DISCUSSION~~ |
- | Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 Suppl 2:S3–9. | + | |
- | Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006; | + | |
- | Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009; | + | |
- | Arzimanoglou A, Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006; | + | |
- | Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006; | + | |
- | Michael CT, Starr JL. Psychosis following initiation of zonisamide. Am J Psychiatry 2007; | + | |
- | Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007; | + | |
- | Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009; | + | |
- | Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; | + |